BridgeBio Pharma, Inc. — Director's Dealing 2024

Jun 25, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-06-21

Reporting Person: Cook Jennifer E. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-21	Stock Option (Right to Buy)	$27.36	A	26014	Acquired	2034-06-20	Common Stock (26014)	Direct

Footnotes

F1: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.